Last reviewed 2026-04-20 · How we verify

Fluidane (BROMINDIONE)

Phase 2 active Small molecule

Fluidane (generic name: BROMINDIONE) is a drug. It is currently in Phase 2 development.

Fluidane works by interacting with a specific molecular target to produce a therapeutic effect.

Fluidane (BROMINDIONE) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The lack of approved indications and generic manufacturers suggests that it may be a patented compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BROMINDIONE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and the key to unlocking a specific lock is a molecule that fits perfectly. Fluidane is like a custom-made key that fits a specific lock, allowing it to turn and produce a desired effect. This process can help to regulate various bodily functions and treat different diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluidane CI brief — competitive landscape report
Fluidane updates RSS · CI watch RSS

Frequently asked questions about Fluidane

What is Fluidane?

Fluidane (BROMINDIONE) is a Small molecule drug.

How does Fluidane work?

Fluidane works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Fluidane?

BROMINDIONE is the generic (nonproprietary) name of Fluidane.

What development phase is Fluidane in?

Fluidane is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing